Annals of Surgical Oncology

, Volume 16, Issue 6, pp 1553–1559 | Cite as

Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab

  • Béatrice Aussilhou
  • Safi Dokmak
  • Sandrine Faivre
  • Valérie Paradis
  • Valérie Vilgrain
  • Jacques Belghiti
Gastrointestinal Oncology



This prospective study evaluated the effect of bevacizumab on the hypertrophy of the future liver remnant (FLR) after portal vein occlusion (PVO) before major hepatectomy for colorectal liver metastases.


Twenty-seven patients with colorectal liver metastases treated with preoperative FOLFOX/FOLFIRI chemotherapy regimen since 2002 were evaluated for the degree of hypertrophy of the FLR after right PVO. The results were compared with a similar group of 13 patients treated since 2006 with a chemotherapeutic regimen including bevacizumab and PVO. The FLR was measured by volumetric computed tomography 4 weeks before and after PVO.


Before PVO, the FLR volumes were similar in the 13 patients who received bevacizumab (bev+) (mean ± standard deviation, 497 ± 136 cm3) and the 27 patients who did not receive bevacizumab (bev−) (511 ± 222 cm3, P = NS). After PVO, the increase in the FLR volume was significantly lower in the bev+ group (561 ± 171 cm3) compared with the bev− group (667 ± 213 cm3, P < .031). In the bev+ group, patients who had received six or more cycles and were ≥60 years old experienced far lower hypertrophy. A right hepatectomy was performed in 29 patients (72%) without mortality and no clinically important differences in morbidity.


Bevacizumab may impair hypertrophy of the FLR after PVO in preparation for major hepatectomy particularly, in patients aged ≥60 years and those who receive six or more cycles of bevacizumab, suggesting that major liver resection should be considered with caution in patients who have received bevacizumab.


Bevacizumab Liver Regeneration Colorectal Liver Metastasis Portal Vein Embolization Major Hepatectomy 


  1. 1.
    Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274–86.PubMedCrossRefGoogle Scholar
  3. 3.
    Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolization before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:1091–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res. 2001;96:173–82.PubMedCrossRefGoogle Scholar
  7. 7.
    D’angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007;14:759–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96–106.PubMedCrossRefGoogle Scholar
  10. 10.
    Van Buren G, Yang A, Dallas N, et al. The effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol. 2008;26:1836–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Redaelli CA, Semela D, Carrick FE, et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol. 2004;40:305–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Dokmak S, Aussilhou B, Faivre S, et al. Hépatectomie pour métastases hépatiques de cancer colorectal après chimiothérapie associée au bevacizumab: série unicentrique de 23 malades (abstract). J Chir. 2007;144.Google Scholar
  13. 13.
    Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Balzan S, Belghiti J, Farges O, Sauvanet A. The “50–50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang F, Lei MP, Oswald TM, et al. The effect of vascular endothelial growth factor on the healing of ischemic skin wounds. Br J Plast Surg. 2003;56:334–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23:16s.Google Scholar
  17. 17.
    Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res. 2002;105:43–7.PubMedCrossRefGoogle Scholar
  18. 18.
    LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independant endothelial protection of liver: role of VEGFR-1. Science 2003;299:890–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94:1386–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Di Stefano DR, de Baere T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005;234:625–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Aussilhou B, Lesurtel M, Sauvanet A, et al. Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. J Gastrointest Surg. 2008;12:297–303.PubMedCrossRefGoogle Scholar
  22. 22.
    Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Rubba-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.CrossRefGoogle Scholar
  25. 25.
    Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Abdalla EK, Curley SA, Vauthey JN, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Bismuth H, Adam R, Levi F, et al. Resection of unresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 2000;66:611–5.Google Scholar
  28. 28.
    Adam R, Delvart V, Pasal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.PubMedCrossRefGoogle Scholar
  29. 29.
    Gagliano N, Grizzi F, Annoni G. Mechanisms of aging and liver functions. Dig Dis. 2007;25:118–23.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Béatrice Aussilhou
    • 1
  • Safi Dokmak
    • 1
  • Sandrine Faivre
    • 2
  • Valérie Paradis
    • 3
  • Valérie Vilgrain
    • 4
  • Jacques Belghiti
    • 1
  1. 1.Department of HPB Surgery, Beaujon Hospital (Assistance Publique-Hôpitaux de Paris)University Paris 7ClichyFrance
  2. 2.Department of Oncology, Beaujon Hospital (Assistance Publique-Hôpitaux de Paris)University Paris 7ClichyFrance
  3. 3.Department of Anatomopathology, Beaujon Hospital (Assistance Publique-Hôpitaux de Paris)University Paris 7ClichyFrance
  4. 4.Department of Radiology, Beaujon Hospital (Assistance Publique-Hôpitaux de Paris)University Paris 7ClichyFrance

Personalised recommendations